Mechanistic considerations in chemopreventive drug development

Journal of Cellular Biochemistry

Volumn 56, Issue 20 S, 1994, Pages 1-24

  Kelloff, Gary J ^a   Boone, Charles W ^a   Steele, Vernon E ^a   Fay, Judith R ^b   Lubet, Ronald A ^a   Crowell, James A ^a   Sigman, Caroline C ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b CCS Associates   (United States)

Author keywords

cancer; Chemoprevention; drug development; mechanism of action

Indexed keywords

ACETYLCYSTEINE; ALLYL SULFIDE; ALPHA TOCOPHEROL; ANTINEOPLASTIC AGENT; ANTIOXIDANT; ASCORBIC ACID; BETA CAROTENE; BUTYRIC ACID; CALCIUM; CAROTENOID; ELLAGIC ACID; FOLIC ACID; GENISTEIN; GLYCYRRHETINIC ACID; ISOTHIOCYANIC ACID DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; OLTIPRAZ; POLYPHENOL DERIVATIVE; PROTEINASE INHIBITOR; RETINOID; SCAVENGER; SELENIUM; TAMOXIFEN; TERPENE;

ANIMAL MODEL; ANTIOXIDANT ACTIVITY; CARCINOGENESIS; CHEMOPROPHYLAXIS; CONFERENCE PAPER; DRUG DETOXIFICATION; DRUG MECHANISM; DRUG RESEARCH; HUMAN; IMMUNOMODULATION; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

EID: 84991189477     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.240560903     Document Type: Article

References (297)

1. Chemoprevention of cancer with retinoids.
2. Chemoprophylaxis.
3. Inhibition of neoplasia by minor dietary constituents.
4. Chemoprevention of cancer.
5. Inhibition of carcinogenesis by minor dietary constituents.
6. Chemoprevention of cancer by naturally occurring and synthetic compounds
7. Progress in cancer chemoprevention: Perspectives on agent selection and short‐term clinical intervention trials.
8. Chemopreventive drug development: Perspectives and progress.
9. Database of inhibitors of carcinogenesis.
10. Inhibition of chemical carcinogenesis
11. Cell‐cycle related hormone carcinogen interaction during chemical carcinogen induction of nodule‐like mammary lesions in organ culture.
12. Characterization of effective chemopreventive agents in mammary gland in vitro using an initiation‐promotion protocol.
13. Development of an anchorage‐independence assay with A427 human lung tumor cells to screen potential chemopreventive agents with different biological activities.
14. Evaluation of a rat tracheal epithelial cell culture assay system to identify respiratory carcinogens.
15. Inhibition of transformation in cultured rat tracheal epithelial cells by potential chemopreventive agents.
16. Chemoprevention of experimental carcinogenesis in animals.
17. 1‐Methyl‐1‐nitrosourea induction of cancer in a localized area of the Syrian golden hamster trachea.
18. The hamster cheek pouch carcinogenesis model.
19. Modification of pancreatic carcinogenesis in the hamster model. XV. Preventive effect of nicotinamide.
20. Screening for chemopreventive (anticarcinogenic) compounds in rodents.
21. Mechanisms of inhibitors of mutagenesis and carcinogenesis. Classification and overview.
22. Strategies for inhibiting multistage carcinogenesis based on signal transduction pathways.
23. Anticaroinogenesis mechanisms, as evaluated in the multistage mouse skin model.
24. Antimutagens and anticarcinogens: A survey of putative interceptor molecules.
25. Cancer prevention: Recent progress and future opportunities.
26. Free radicals as targets for cancer chemoprevention: Prospects and problems
27. Ornithine decarboxylase, a possible target for human cancer prevention
28. Arachidonic acid metabolism
29. Calcium ameliorates the toxic effect of deoxycholic acid on colonic epithelium.
30. Calcium inhibits the damaging and compensatory proliferative effects of fatty acids on mouse colon epithelium.
31. Calcium, vitamin D, and colon cancer.
32. Colon cancer and dietary fat, phosphate, and calcium: A hypothesis.
33. Structure‐activity relationships of isothiocyanates as mechanism‐based inhibitors of 4‐(methylnitrosamino)‐1‐(3‐pyridyl)‐1‐butanone‐induced lung tumorigenesis in A/J mice.
34. Effects of dietary compounds on α‐hydroxylation of N‐nitrosopyrrolidine and N′‐nitrosonornicotine in rat target tissues.
35. Effects of dietary indoles and isothiocyanates on N‐nitrosodimethylamine and 4‐(methylnitrosamino)‐1‐(3‐pyridyl)‐1‐butanone α‐hydroxylation and DNA methylation in rat liver.
36. 6‐methylguanine formation, and metabolism of the tobacco‐specific nitrosamine 4‐(methylnitrosamino)‐1‐(3‐pyridyl)‐1‐butanone in A/J mouse lung.
37. Inhibition of 4‐(methylnitrosamino)‐1‐(3‐pyridyl)‐1‐butanone‐induced DNA adduct formation and tumorigenicity in the lung of F344 rat by dietary phenethyl isothiocyanate.
38. Chemoprevention of lung carcinogenesis by aromatic isothiocyanates
39. Effects of alkyl chain length on the inhibition of NNK‐induced lung neoplasia in A/J mice by arylalkyl isothiocyanates.
40. Structure‐activity relationships for inhibition of 4‐(methylnitrosamino)‐1‐(3‐pyridyl)‐1‐butanone lung tumorigenesis by arylalkyl isothiocyanates in A/J mice.
41. Inhibition of aromatase cytochrome P‐450 (estrogen synthetase) by derivatives of alpha‐naphthoflavone.
42. Mechanism and inhibition of cytochrome P‐450 aromatase.
43. Effects of the aromatase inhibitor 4‐hydroxyandrostenedione and the antiandrogen flutamide on grwoth and steroid levels in DMBA‐induced rat mammary tumors.
44. Novel aromatase inhibitors.
45. Regulatory mechanisms of monofunctional and bifunctionalanticarcinogenic enzyme inducers inmurine liver.
46. Chemical protection against cancer by induction of electrophile detoxication (Phase II) enzymes
47. Protective role of glutathione and glutathione transferases in mutagenesis and carcinogenesis.
48. Glutathione peroxidase
49. Inhibition of the effects of 12‐ O‐tetradecanoylphorbol‐13‐acetate on mouse epidermal glutathione peroxidase and ornithine decarboxylase activities by glutathione level‐raising agents and selenium‐containing compounds.
50. Free radical tissue damage: Protective role of antioxidant nutrients.
51. Inhibition by dietary selenium of colon cancer induced in the rat by bis(2‐oxopropyl)‐nitrosamine.
52. Biochemical and clinical effects of selenium on dimethyl‐hydrazine‐induced colon cancer in rats.
53. Mechanisms of selenium inhibition of tumorigenesis.
54. Effect of dietary excess of inorganic selenium during initiation and postinitiation phases of colon carcinogenesis in F344 rats.
55. Inhibitory effect of dietary selenium on carcinogenesis in rat glandular stomach induced by N‐methyl‐ N′‐nitro‐ N‐nitrosoguanidine.
56. Effect of dietary indole‐3‐carbinol on intestinal and hepatic monooxy‐genase, glutathione S‐transferase and epoxide hydrolase activities in the rat.
57. Altered estrogen metabolism and excretion in humans following consumption of indole‐3‐carbinol.
58. Chemoprotection by oltipraz and other dithiolethiones
59. 1 binding to DNA in vivo in rats fed phenolic antioxidants, ethoxyquin, and a dithiolthione.
60. Inhibition of N‐methyl‐ N‐nitrosourea‐induced mutagenicity and DNA methylaton by ellagic acid.
61. 6‐methylguanine by dietary ellagic acid in rats.
62. ADP‐ribosylation is involved in the integration of foreign DNA into the mammalian cell genome.
63. Response of mammalian ADP‐ribosyl transferase to lymphocyte stimulation, mutagen treatment and cell cycling.
64. Depletion of adenosine diphosphate‐ribosyl transferase activity in rat liver during exposure to N‐2‐acetylaminofluorene: Effect of thiols.
65. A protease inhibitor blocks SOS functions in Escherichia coli: Antipain prevents lambda repressor inactivation, ultraviolet mutagenesis, and filamentous growth.
66. Pyrene acts as a cocarcinogen with the carcinogens benzo[a]pyrene, beta‐propiolactone and radiation in the induction of malignant transformation in cultured mouse fibroblasts, soybean extract containing the Bowman‐Birk inhibitor acts as an anticarcinogen.
67. The nature of oxidants and antioxidant systems in the inhibition of mutation and cancer.
68. Mechanisms of inhibition of free‐radical processes in mutagenesis and carcinogenesis.
69. DNA damage and oxygen radical toxicity.
70. Genetic effects of thymine glycol: Sitespecific mutagenesis and molecular modeling studies.
71. Free‐radical‐mediated DNA binding.
72. Peroxyl free radicals: Potential mediators of tumor initiation and promotion.
73. Active oxygen acts as a promoter of transformation in mouse embryo C3H/10T1/2/C18 fibroblasts.
74. Early superoxide dismutase‐sensitive event promotes neoplastic transformation in mouse epidermal JB6 cells.
75. Oxidant stress induces the proto‐oncogenes c‐fos and c‐ myc in mouse epidermal cells.
76. The development of secondary pathology with free radical reactions as threshold mechanism.
77. Inflammation and cancer: Role of phagocyte‐generated oxidants in carcinogenesis.
78. Why is the hydroxyl radical the only radical that commonly adds to DNA? Hypothesis: It has a rare combination of high electrophilicity, high thermochemical reactivity, and a mode of production that can occur near DNA.
79. Mutagenicity of active oxygen species in bacteria and its enzymatic or chemical inhibition.
80. Chemistry of singlet oxygen. X. Carotenoid quenching parallels biological protection.
81. Quenching of singlet oxygen
82. Free radicals and singlet oxygen scavengers: Reaction of a peroxy‐radical with beta‐carotene, diphenyl furan and 1,4‐diazobicyclo(2,2,2)‐octane.
83. beta‐Carotene: An unusual type of lipid antioxidant.
84. Antioxidant functions of carotenoids.
85. Antioxidant action of carotenoids.
86. 2+/ascorbate generated free radicals: Fffects of partial pressures of oxygen.
87. Cyclosporin A and its analogues as modifiers of adriamycin and vincristine resistance in a multi‐drug re‐sistant human lung cancer cell line.
88. Autoxidation of biological molecules. 1. The antioxidant activity of vitamin E and related chain‐breaking phenolic antioxidants in vitro.
89. Vitamin E: Interactions with free radicals and ascorbate.
90. Cancer and free radicals.
91. Current perspectives of singlet oxygen detection in biological environments.
92. Current strategies of cancer chemoprevention: 13th Sapporo Cancer Seminar.
93. Aspirin and the potential role of prosta‐glandins in colon cancer.
94. Inhibition of development of methylnitrosourea‐induced rat colon tumors by indomethacin treatment.
95. The suppressive effect of piroxicam on autochthonous intestinal tumors in the rat.
96. Inhibition of intestinal carcinogenesis in rats: Effect of difluoro‐methylornithine with piroxicam or fish oil.
97. A protective effect of sulindac against chemically‐induced primary colonic tumours in mice.
98. Inhibition of colon carcinogenesis by prostaglandin synthesis inhibitors and related compounds.
99. Antitumor effects of inhibitors of arachidonic acid cascade on experimentally‐induced intestinal tumors.
100. Dose‐related inhibition of colon carcinogenesis by dietary piroxicam, a non‐steroidal antiinflammatory drug, during different stages of rat colon tumor development.
101. Inhibitory effect of aspirin on azoxymethane‐induced colon carcinogenesis in F344 rats.
102. Chemoprevention of OH‐BBN‐induced bladder cancer in mice by piroxicam.
103. NSAIDs: Time to re‐evaluate gut toxicity.
104. Analgesic‐antipyretics and antiinflammatory agents; drugs employed in the treatment of rheumatoid arthritis and gout
105. Selective inhibition of inducible cyclo‐oxygenase 2 in vivo is antiinflammatory and nonulcerogenic.
106. NS‐398, a new antiinflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX‐2) activity in vitro.
107. Recent advances in the development of anticancer drugs that act against signalling pathways.
108. The eicosanoids and their biochemical mechanisms of action.
109. Arachidonic acid cascade inhibitors in chemoprevention of human colon cancer: Preliminary studies
110. Suppression of a human T‐cell mitogenesis by prostaglandin.
111. Prostaglandin suppression of mitogen‐stimulated lymphocytes in vitro.
112. Calcium: Driver of cell cycles, trigger of differentiation, and killer of cells
113. Cell‐signalling targets for antitumour drug development.
114. The role of protein kinase C in transmembrane signalling.
115. Modulation of keratinocyte proliferation in vitro by endogenous prostaglandin synthesis.
116. Stimulation by carcinogens and promoters of prostaglandin production by dog kidney (MDCK) cells in culture.
117. Elevated prostaglandin synthetase activity in methylchol‐anthrene‐tranformed mouse BALB/3T3.
118. Eicosanoids and multistage carcinogenesis in NMRI mouse skin: Role of prostaglandins E and F in conversion (first stage of tumor promotion) and promotion and promotion (second stage of tumor promotion).
119. Molecular mechanisms of action of steroid/thyroid receptor superfamily members.
120. Mechanisms of antihormone action.
121. The strategic use of antiestrogens to control the development and growth of breast cancer.
122. Soy intake and cancer risk: A review of the in vitro and in vivo data.
123. Transforming growth factor β.
124. Reversible inhibition of mammary gland growth by transforming growth factor‐β.
125. Interactions of retinoids and transforming growth factor β in the chemoprevention of cancer
126. Type β transforming growth factor reversibly inhibits the early proliferative response to partial hepatectomy in the rat.
127. Effects of growth factors on an intestinal epithelial cell line: Transforming growth factor beta inhibits proliferation and stimulates differentiation.
128. Evidence that transforming growth factor‐beta is a hormonally regulated negative growth factor in human breast cancer cells.
129. Complex regulation of TGFβ expression by retinoic acid in the vitamin A‐deficient rat.
130. Tamoxifen reduces serum insulin‐like growth factor I (IGF‐I).
131. Insulin‐like growth factors and cancer.
132. Effect of tamoxifen on plasma insulin‐like growth factor I in patients with breast cancer.
133. Genistein, a specific inhibitor of tyrosine‐specific protein kinases.
134. Direct mutagenesis of Ha‐ ras‐1 oncogenes by N‐nitroso‐ N‐methylurea during initiation of mammary carcinogenesis in rats.
135. Expression of the c‐Ha‐ras and neu oncogenes in DMBA‐induced anti‐estrogen‐treated rat mammary tumors.
136. Limonene‐induced regression of mammary carcinomas.
137. Selective inhibition of isoprenylation of 21–26‐kDa proteins by the anticarcinogen d‐limonene and its metabolites.
138. Enhanced inhibition of protein isoprenylation and tumor growth by perillyl alcohol, an hydroxylated analog of D‐limonene.
139. Protein farnesyltransferase inhibitors block the growth of ras‐dependent tumors in nude mice.
140. Enzymic conversion of farnesyl pyrophosphate to squalene.
141. Inhibition of azoxymethane‐induced neoplasia of the large bowel by 3‐hydroxy‐3,7,11‐trimethyl‐1,6,10‐dodecatriene (nerolidol).
142. Lovastatin, a cholesterol biosynthesis inhibitor, inhibits the growth of human H‐ ras oncogene transformed cells in nude mice.
143. Role of arachidonic acid metabolism in the mitogenic response of BALB/c 3T3 fibroblasts to epidermal growth factor.
144. Mitogenic signaling by epidermal growth factor (EGF), but not platelet‐derived growth factor, requires arachidonic acid metabolism in BALB/c 3T3 cells.
145. Workshop report from the Division of Cancer Etiology, National Cancer Institute, National Institutes of Health. Protease inhibitors as cancer chemopreventive agents.
146. Polyamine metabolism and its importance in neoplastic growth and as a target for chemotherapy.
147. Polyamine metabolism and function.
148. Phorbol esters stimulate DNA synthesis and ornithine decarboxylase activity in mouse epidermal cell cultures.
149. Kinetic changes in mucosal ornithine decarboxylase activity during azoxymethane‐induced colonic carcinogenesis in the rat.
150. Polyamine metabolism in normal and in virus‐transformed chick embryo fibroblasts.
151. Increased ornithine decarboxylase activity in murine sarcoma virus infected cells.
152. Ornithine decarboxylase induction during B1 progression of normal and Rous sarcoma virus‐transformed cells.
153. The mechanisms of ornithine decarboxylase deregulation in c‐Ha‐ ras oncogene‐transformed NIH 3T3 cells.
154. Modulation of polyamine biosynthesis and transport by oncogene transfection.
155. The cellular response to induction of the p21c‐Ha‐ras oncoprotein includes stimulation of jun gene expression.
156. Activation of the neu tyrosine kinase induces the fos/jun transcription factor complex, the glucose transporter and ornithine decarboxylase.
157. Ornithine decarboxylase activity is critical for cell transformation.
158. The induction of ornithine decarboxylase as an early, possibly obligatory, event in mouse skin carcinogenesis.
159. Inhibition of tumor promoter 12‐ O‐tetra‐decanoylphorbol‐13‐acetate‐induced synthesis of epidermal ornithine decarboxylase messenger RNA and diacylglycerol‐promoted mouse skin tumor formation by retinoic acid.
160. Involvement of protein kinase C activation in ornithine decarboxylase gene expression in primary culture of newborn mouse epidermal cells and in skin tumor promotion by 12‐ O‐tetradecanoylphorbol‐13‐acetate.
161. Involvement of protein kinase C in the transcriptional regulation of ornithine decarboxylase gene expression by 12‐ O‐tetradecanoylphorbol‐13‐acetate in T24 human bladder carcinoma cells.
162. Lack of a role of DNA methylation in tumor promoter 12‐ O‐tetradecanoyl‐phorbol‐130‐acetate‐induced synthesis of ornithine decarboxylase messenger RNA in T24 cells.
163. Inhibition by prostaglandin synthesis inhibitors of the induction of epidermal ornithine decarboxylase activity, the accumulation of prostaglandins, and tumor promotion caused by 12‐ O‐tetradecanoylphorbol‐13‐acetate.
164. Inhibition of 12‐ O‐tetradecanoylphorbol‐13‐acetate‐induced epidermal ornithine decarboxylase activity by phospholipase A2 inhibitors and lipoxygenase inhibitor.
165. Inhibition by 2(3)‐tert‐butyl‐4‐hydroxyanisole and other antioxidants of epidermal ornithine decarboxylase activity induced by 12‐ O‐tetradecanoylphorbol‐13‐acetate.
166. Inhibition of skin tumor promoter‐caused induction of epidermal ornithine decarboxylase in SENCAR mice by polyphenolic fraction isolated from green tea and its individual epicatechin derivative.
167. Vitamin A acid (retinoic acid), a potent inhibitor of 12‐ O‐tetradecanoylphorbol‐13‐acetate‐induced ornithine decar‐boxylase activity in mouse epidermis.
168. Correlation of the inhibition by retinoids of tumor promoter‐induced mouse epidermal ornithine decarboxylase activity and of skin tumor promotion.
169. Biological evaluation of retinoyl amino acids‐suppression of tumor formation and ODC enzyme induction.
170. Cure of Trypanosoma brucei brucei and Trypanosoma brucei rhodesiense infections in mice with an irreversible inhibitor of S‐adenosylmethionine decarboxylase.
171. Inhibition of polyamine metabolism and the consequent effects on cell proliferation
172. Retinoids and their receptors in differentiation, embryogenesis, and neoplasia.
173. Structure‐activity relationships of retinoids in hamster tracheal organ culture.
174. Vitamin A deficiency and keratin biosynthesis in cultured hamster trachea.
175. Differentiation of tracheal mucociliary epithelium in primary cell culture recapitulates normal fetal development and regeneration following injury in hamsters.
176. Induction of terminal differentiation in human promyelocytic leukemia cells by tumor‐promoting agents.
177. Induction of differentiation of the human promyelocytic leukemia cell line (HL‐60) by retinoic acid.
178. Induction of differentiation of cultured human promyelocytic leukemia cells by retinoids.
179. Retinoic acid‐induced expression of tissue transglutaminase in human promyelocytic leukemia (HL‐60) cells.
180. New benzoic acid derivatives with retinoid activity: Lack of direct correlation between biological activity and binding to cellular retinoic acid binding protein.
181. Inhibition of ornithine decarboxylase by retinoic acid and difluoromethyl‐ornithine in relation to their effects on differentiation and proliferation.
182. Cell interactions modulate embryonal carcinoma cell differentiation into parietal or visceral endoderm.
183. Synthesis of laminin and entactin by F9 cells induced with retinoic acid and dibutyryl cyclic AMP.
184. Changes in the rate of laminin and entactin synthesis in F9 embryonal carcinoma cells treated with retinoic acid and cyclic AMP.
185. In vitro binding of retinol to rat‐tissue components.
186. A retinoic‐acid binding protein from chick embryo skin.
187. Isolation, partial purification and characterization of nuclear retinoic acid receptors from chick skin.
188. Retinoids and cancer prevention.
189. Interactions of retinoids and transforming growth factor‐beta in regulation of cell differentiation and proliferation.
190. Relationships of calcium and vitamin D to colon cancer
191. Clonal growth and serial propagation of rat esophageal epithelial cells.
192. Calcium regulation of growth and differentiation of mouse epidermal cells in culture.
193. Calcium regulation of normal human mammary epithelial cell growth in culture.
194. A simplified method for passage and long‐term growth of human mammary epithelial cells.
195. Dietary cholesterol deprivation improves survival and reduces incidence of metastatic colon cancer in dimethylhydrazine‐pretreated rats.
196. 3.
197. 3 induces differentiation of human myeloid leukemia cells.
198. 3: In vivo and in vitro effects on human preleukemic and leukemic cells.
199. 3
200. The vitamin D‐induced differentiation of HL‐60 cells: Structural requirements.
201. Induction of monocytic differentiation of HL‐60 cells by 1,25‐dihydroxyvitamin D analogs.
202. An investigation into the mechanism of co‐carcinogenesis of dietary cholesterol during the induction of colon cancer in rats by 1,2‐dimethylhydrazine.
203. 3, retinoic acid, dexamethasone, and a tumor‐promoting phorbol ester on the functional capability of P388D1 cells: Phagocytosis and transglutaminase activity.
204. Differential response of premalignant epithelial cell classes to phorbol ester tumor promoters and to deoxycholic acid.
205. Transient reversion of ras oncogene‐induced cell transformation by antibodies specific for amino acid 12 of ras protein.
206. Prostaglandins and cancer: An update.
207. Subversion of immune system by tumor cells and role of prostaglandins.
208. Alteration of tumor growth by aspirin and indomethacin: Studies with two transplantable tumors in mouse.
209. Tumor‐mediated immunosuppression: Prevention by inhibitors of prostaglandin synthesis.
210. Mechanism of inhibition of tumour growth by aspirin and indomethacin.
211. Cancer growth, response to treatment and survival time in mice: Beneficial effect of the prostaglandin synthesis inhibitor flurbiprofen.
212. Inhibition of murine natural killer cell activity by prostaglandins.
213. Indomethacin‐mediated enhancement of lymphocyte response to mitogens in healthy subjects and lung cancer patients.
214. Indomethacin enhancement of immunocompetence in melanoma patients.
215. 2 production by suppressor monocytes in head and neck cancer patients.
216. 2‐mediated suppression of cellular immunity in colon cancer patients.
217. Prostaglandin and thromboxane synthesis by Lewis lung carcinoma during growth.
218. Retinoids as chemopreventive and anticancer agents in intact animals (review).
219. Effect of vitamin E on immune function
220. Vitamin E and immune regulation.
221. Alpha‐tocopherol alters the distribution of Langerhans cells in DMBA‐treated hamster cheek pouch epithelium.
222. Tumor necrosis factor in experimental cancer regression with alphatocopherol, beta‐carotene, canthaxanthin and algae extract.
223. Selenium and immune responses.
224. Role of inhibition of intercellular communication in caroinogenesis.
225. Use of cell culture systems for mechanistic studies of chemopreventive agents
226. Junctional intercellular communication and the control of growth.
227. Growth inhibition of transformed cells correlates with their junctional communication with normal cells.
228. The actions of retinoids on cellular growth correlate with their actions on gap junctional communication.
229. Carotenoids enhance gap junctional communication and inhibit lipid peroxidation in C3H/10T1/2 cells: Relationship to their cancer chemopreventive action.
230. Enhancement of gap junctional communication by retinoids correlates with their ability to inhibit neoplastic transformation.
231. Genetics of human cancer.
232. Inactivation of the retinoblastoma susceptibility gene in human breast cancers.
233. Structural rearrangement of the retinoblastoma gene in human breast carcinoma.
234. Frequent inactivation of the retinoblastoma anti‐oncogene is restricted to a subset of human tumor cells.
235. Tumor suppressor genes.
236. Progress toward human gene therapy.
237. Tumor suppressor genes: The p53 and retinoblastoma sensitivity genes and gene products.
238. Abnormal structure and expression of p53 gene in human hepatocellular carcinoma.
239. Increased expression of mutant forms of p53 oncogene in primary lung cancer.
240. Mechanisms of p53 loss in human sarcomas.
241. Gene therapy of cancer through restoration of tumor‐suppressor functions?
242. p53 Mutations in breast cancer.
243. Clinical implications of the p53 tumor‐suppressor gene.
244. Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis.
245. Aniridia‐Wilms' tumor association: Evidence for specific deletion of 11p13.
246. The Aniridia‐Wilms tumor association: The critical role of chromosome band 11p13.
247. Isolation and characteriztion of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus.
248. A genetic model for colorectal tumorigenesis.
249. Apoptosis. Biochemical events and relevance to cancer chemotherapy.
250. Cell death by apoptosis and its protective role against disease.
251. Wild‐type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin‐6.
252. The involvement of oncogenes and tumor suppressor genes in the control of apoptosis.
253. Effect of transforming growth factor β on cell death of cultured rat hepatocytes.
254. Inhibition of DNA fragmentation in thymocytes and isolated thymocyte nuclei by agents that stimulate protein kinase C.
255. Rescue from programmed cell death in leukemic and normal myeloid cells.
256. Determination of the length of the histological stages of apoptosis in normal liver and in altered hepatic foci of rats.
257. Cell death: The signifigance of apoptosis.
258. Programming cell death during regression of PC‐82 human prostate cancer following androgen ablation.
259. Control of cell death (apoptosis) by diethylstilbestrol in an estrogen‐dependent kidney tumor.
260. Programmed cell death during regression of the MCF‐7 human breast cancer following estrogen ablation.
261. Programmed cell death (apoptosis) in pancreatic cancers of hamsters after treatment with analogs of both luteinizing hormone‐releasing hormone and somatostatin.
262. Methyl groups in carcinogenesis: Effects on DNA methylation and gene expression.
263. Hepatocarcinogenesis in rats fed methyl‐deficient, amino acid‐defined diets.
264. The induction of liver cancer by dietary deficiency of choline and methionine without added carcinogens.
265. Hepatocarcinogenic and promoting action of a choline‐devoid diet in the rat.
266. Labile methyl groups and the promotion of cancer.
267. The effect of methionine on the progression of hepatocellular carcinoma induced by ethionine.
268. Altered methionine metabolism, DNA methylation and oncogene expression in carcinogenesis‐A review and synthesis.
269. Suppression by methionine and choline of onco‐fetal patterns of liver tRNA methyltransferase activities in carcinogentreated rats.
270. Altered expression of retrovirus‐like sequences and cellular oncogenes in mice fed methyl‐deficient diets.
271. Alterations in expression and methylation of specific genes in livers of rats fed a cancer promoting methyl‐deficient diet.
272. Early changes in nucleic acid methylation and gene expression in livers of rats fed cancerpromoting, methyl‐deficient diets.
273. Altered expression of oncogenes in rats fed a methyl‐deficient diet.
274. Expression of endogenous retrovirus‐like sequences and cellular oncogenes during phenobarbital treatment and regeneration in rat liver.
275. Oncogene expression in rat hepatomas and during hepatocarcinogenesis.
276. Expression of c‐Ki‐ ras, c‐Ha‐ras, and c‐ myc in specific cell types during hepatocarcinogenesis.
277. Rapid and reversible changes in DNA methylation and gene expression in livers of rats fed cancer‐promoting methyl‐deficient diets.
278. Rapid appearance of hypomethylated DNA in livers of rats fed cancer‐promoting, methyl‐deficient diets.
279. c‐H‐ras and c‐K‐ ras gene hypomethylation in the livers and hepatomas of rats fed methyl‐deficient, amino acid‐defined diets.
280. A new theory of carcinogenesis.
281. 5‐Methyl‐cytosine depletion during tumour development: An extension of the miscoding concept.
282. Cellular targets and host genes in multistage carcinogenesis.
283. The role of DNA methylation in cancer.
284. Angiogenesis.
285. What is the evidence that tumors are angiogenesis dependent?
286. Induction of angiogenesis during the transition from hyperplasia to neoplasia.
287. 2 and angiogenesis.
288. 15‐Hydroxyeicosa‐tetraenoic acid stimulates migration of human retinal microvessel endothelium in vitro and neovascularization in vivo.
289. Chemoprevention of cancer: Protease inhibitors.
290. Tumor invasion and metastasis: An imbalance of positive and negative regulation.
291. Drosophila gene that is homologous to a mammalian gene associated with tumor metastasis codes for a nucleoside diphosphate kinase.
292. Expression of the antimetastatic gene nm23 in human breast cancer: an association with good prognosis.
293. Association of low nm23 RNA levels in human primary infiltrating ductal breast carcinomas with lymph node involvement and other histopathological indicators of high metastatic potential.
294. Neural computing in cancer drug development: Predicting mechanism of action.